Evaluation of the adherence to antidiabetic  medications among Iraqi patients with T2DM using  the Iraqi antidiabetic medication adherence scale  (IADMAS)

Hussain Saad; Al Tukmagi Haydar; Abdulrahman Zainab; Sadeq Maryem; Hashim Dania; Kadhim Rand; Muayad Kubba Mohammed; Al Tukmagi Dur

doi:https://dx.doi.org/10.26650/IstanbulJPharm.2021.870571

Araştırma Makalesi

DOI :10.26650/IstanbulJPharm.2021.870571 IUP :10.26650/IstanbulJPharm.2021.870571 Tam Metin (PDF)

Evaluation of the adherence to antidiabetic medications among Iraqi patients with T2DM using the Iraqi antidiabetic medication adherence scale (IADMAS)

Saad Abdulrahman Hussain, Haydar Fakhri Al Tukmagi, Zainab Saad Abdulrahman, Maryem Maythem Sadeq, Dania Natheer Hashim, Rand Sabah Kadhim, Mohammed Mahdi Muayad Kubba, Dur Haydar Al Tukmagi

Background and Aims: Management of diabetes is a multifactorial process, and adherence to treatment programs plays a role in glycemic control. The present study evaluates the adherence rate to the antidiabetic medications with a newly developed scale and patients’ HbA1c levels among Iraqi patients with type-2 diabetes. Methods: A cross-sectional study among adult patients receiving diabetic care in public and private healthcare settings within Baghdad City was conducted. The medication adherence was evaluated using the Iraqi Antidiabetic Medication Adherence Scale (IADMAS) to determine the factors associated with non-adherence to anti-diabetic medications. Glycated hemoglobin (HbA1c) levels of the participants were used as an indicator of glycemic status. Results: The outcome measures include the comparison between glycemic status and the claims of antidiabetic medication adherence of patients with T2DM, in addition to the expected benefits to clinical practice. A total of 442 patients with type 2 diabetes participated in the study and responded by completing the given questionnaire (response rate: 96.1%). The prevalence of non-adherence to medication was reported to be no more than 30%. Adherence based on HbA1c values reflected a high false-positive value of adherence with an extremely high true negative value. The adherence of Iraqi patients to their medications demonstrated a high negative predictive value (0.905) and a high sensitivity (0.928) with low specificity (0.156) values. Conclusion: The use of IADMAS in this study failed to confirm the consistency between the apparent claims of adherence to anti-diabetic medications and the HbA1c value as a marker of glycemic control.

Anahtar Kelimeler: T2DM, antidiabetic medications, patient adherence, IADMAS

Referanslar

Abebe, S. M., Berhane, Y. & Worku, A. (2014). Barriers to diabetes medication adherence in North West Ethiopia. SpringerPlus, 3(1), 195. https://doi:10.1186/2193-1801-3-195 google scholar
Ahmad, N. S., Ramli, A., Islahudin, F. & Paraidathathu, T. (2013). Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia. Patient Preference and Adherence, 7, 525-530. https://doi:10.2147/PPA.S44698 google scholar
American Diabetes Association. (2020). Classification and diagno-sis of diabetes: Standards of Medical Care in Diabetes-2020. Dia-betes Care, 43(Suppl. 1), S14-S31. https://doi:10.2337/dc20-S002 google scholar
Aminde, L. N., Tindong, M., Ngwasiri, C. A., Aminde, J. A., Njim, T., Fondong, A. A., & Takah, N. F. (2019). Adherence to antidiabetic medication and factors associated with non-adherence among patients with type-2 diabetes mellitus in two regional hospi-tals in Cameroon. BMC Endocrine Disorders, 19(1), 35. https:// doi:10.1186/s12902-019-0360-9 google scholar
Bagonza, J., Rutebemberwa, E. & Bazeyo, W. (2015). Adherence to anti-diabetic medication among patients with diabetes in east-ern Uganda; a cross sectional study. BMC Health Services Research, 15(1), 168. https://doi:10.1186/s12913-015-0820-5 google scholar
Bertoni, A. G., Krop, J. S., Anderson, G. F. & Brancati, F. L. (2002). Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care, 25(3), 471-475. https://doi:10.2337/dia-care.25.3.471 google scholar
Bi, Y., Wang, T., Xu, M., Xu, Y., Li, M., Lu, J. ...Ning, G. (2012). Ad-vanced research on risk factors of type 2 diabetes. Diabetes Metabolism Research and Reviews, 28(Suppl. 2), 32-39. https:// doi:10.1002/dmrr.2352 google scholar
Capoccia, K., Odegard, P. S. & Letassy, N. (2016). Medication adherence with diabetes medication: a systematic review of the literature. The Diabetes Educator, 42(1), 34-71. https:// doi:10.1177/0145721715619038 google scholar
Chan, M. (2017). Obesity and diabetes: the slow-motion disaster. Milbank Quarterly, 95(1), 11-14. https://doi:10.1111/1468-0009.12238 google scholar
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R. .Mirza, W. (2017). Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Frontiers in Endocrinology, 8, 6. https://doi:10.3389/fendo.2017.00006 google scholar
Chia, L. R., Schlenk, E. A. & Dunbar-Jacob, J. (2006). Effect of personal and cultural beliefs on medication adherence in the elderly. Drugs & Aging, 23(3), 191-202. https://doi:10.2165/00002512-200623030-00002 google scholar
Chung, W. W., Chua, S. S., Lai, P. S. M. & Morisky, D. (2015). The Ma-laysian Medication Adherence Scale (MALMAS): concurrent valid-ity using a clinical measure among people with type 2 diabetes in Malaysia. PLoS One, 10(4), e0124275. https://doi:10.1371/journal. pone.0124275 google scholar
de Vries McClintock, H. F., Morales, K. H., Small, D. S. & Bogner, H. R. (2016). Patterns of adherence to oral hypoglycemic agents and glucose control among primary care patients with type 2 diabe-tes. Behavioral Medicine, 42(2), 63-71. https://doi:10.1080/089642 89.2014.904767 google scholar
Del Brutto, O. H., & Mera, R. M. (2016). The importance of people compliance (social desirability bias) in the assessment of epi-lepsy prevalence in rural areas of developing countries. Results of the Atahualpa Project. Epilepsia, 57(12), e221-e224. https:// doi:10.1111/epi.13594 google scholar
Egede, L. E., Gebregziabher, M., Dismuke, C. E., Lynch, C. P., Axon, R. N., Zhao, Y. ... Mauldin P. D. (2012). Medication nonadherence in diabetes: longitudinal effects on costs and potential cost sav-ings from improvement. Diabetes Care, 35(Suppl. 1), 2533-2539. https://doi:10.2337/dc12-0572 google scholar
Egede, L. E., Gebregziabher, M., Echols, C. & Lynch, C. P. (2014). Longitudinal effects of medication nonadherence on glyce-mic control. Annals of Pharmacotherapy, 48(5), 562-570. https:// doi:10.1177/1060028014526362 google scholar
Forbes, J. M. & Cooper, M. E. (2013). Mechanisms of diabetic complications. Physiological Reviews, 93(1), 137-188. https:// doi:10.1152/physrev.00045.2011 google scholar
Grant, R. W. & Kirkman, M. S. (2015). Trends in the evidence level for the American Diabetes Association’s “Standards of Medical Care in Diabetes” from 2005 to 2014. Diabetes Care, 38(1), 6-8. https://doi:10.2337/dc14-2142 google scholar
Heissam, K., Abuamer, Z., & El-Dahshan, N. (2015). Patterns and ob-stacles to oral antidiabetic medications adherence among type 2 diabetics in Ismailia, Egypt: a cross section study. Pan African Med-ical Journal, 20, 177. https://doi:10.11604/pamj.2015.20.177.4025 Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., Reese, D., Linder, R., Ahrens, S. & Magid, D. J. (2006). Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mel-litus. Achieve of Internal Medicine, 166(17), 1836-1841. https:// doi:10.1001/archinte.166.17.1836 google scholar
Kaiser, A. B., Zhang, N. & Van der Pluijm, W. (2018). Global prev-alence of type 2 diabetes over the next ten years (2018-2028). Diabetes, 67 (Suppl. 1), 202. https://doi.org/10.2337/db18-202-LB Krapek, K., King, K., Warren, S. S., George, K. G., Caputo, D. A., Mi-helich, K., . Lubowski, T. J. (2004). Medication adherence and associated hemoglobin A1c in type 2 diabetes. Annals of Pharma-cotherapy, 38(9), 1357-1362. https://doi:10.1345/aph.1D612 google scholar
Lingam, R., & Scott, J. (2002). Treatment non-adherence in affec-tive disorders. Acta Psychiatrica Scandinavica, 105(3), 164-172. https://doi:10.1034/j.1600-0447.2002.1r084.x google scholar
Mikhael, E. M., Hussain, S. A., Shawky, N. & Hassali, M. A. (2019). Va-lidity and reliability of anti-diabetic medication adherence scale among patients with diabetes in Baghdad, Iraq: a pilot study. BMJ Open Diabetes Research & Care, 7(1), e000658. https://:doi:10.1136/ bmjdrc-2019-000658 google scholar
Musenge, E. M., Michelo, C., Mudenda, B., & Manankov, A. (2016). Glycaemic Control and Associated Self-Management Behaviours in Diabetic Outpatients: A Hospital Based Observation Study in Lusaka, Zambia. Journal of Diabetes Research, 2016, 1-9. https:// doi:10.1155/2016/7934654 google scholar
Nguyen, T. M. U., Caze, A. L. & Cottrell, N. (2014). What are validat-ed self-report adherence scales measuring? a systematic review. British Journal of Clinical Pharmacology, 77(3), 427-445. https:// doi:10.1111/bcp.12194 google scholar
Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H. .Makaroff, L. E. (2017). IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice, 128, 40-50. https:// doi:10.1016/j.diabres.2017.03.024 google scholar
Polonsky, W. H. & Henry, R. R. (2016). Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Preference and Adherence, 2016, 12991307. https://doi:10.2147/PPA.S106821 google scholar
Sarwar, N., Gao, P., Kondapally Seshasai, S. R., Gobin, R., Kaptoge, S. & Di Angelantonio, E. (2010). The Emerging Risk Factors Col-laboration. Diabetes mellitus, fasting blood glucose concentra-tion, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet, 375(9733), 2215-2222. https:// doi.org/10.1016/S0140-6736(10)60484-9 google scholar
Schectman, J. M., Nadkarni, M. M. & Voss, J. D. (2002). The associa-tion between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care, 25(6), 1015-1021. https:// doi:10.2337/diacare.25.6.1015 google scholar
Sodihardjo-Yuen, F., van Dijk, L., Wensing, M., De Smet, P. A. & Tei-chert, M. (2017). Use of pharmacy dispensing data to measure adherence and identify non-adherence with oral hypoglycemic agents. European Journal of Clinical Pharmacology, 73(2), 205-213. https://doi:10.1007/s00228-016-2149-3 google scholar
Stirratt, M. J., Dunbar-Jacob, J., Crane, H. M., Simoni, J. M., Cza-jkowski, S., Hilliardet, M. E. .Nilsen, W. J. (2015). Self-report mea-sures of medication adherence behavior: recommendations on optimal use. Translational Behavioral Medicine, 5(4), 470-482. https://doi:10.1007/s13142-015-0315-2 google scholar
Stolar, M. (2010). Glycemic control and complications in type 2 diabetes mellitus. American Journal of Medicine, 123(Suppl. 3), S3-S11. https://doi:10.1016/j.amjmed.2009.12.004 google scholar
Whooley, M. A., Avins, A. L., Miranda, J. & Browner, W. S. (1997). Case-finding instruments for depression. Two questions are as good as many. Journal of General Internal Medicine, 12(7), 439-445. https://doi:10.1046/j.1525-1497.1997.00076.x google scholar
Wilke, T., Groth, A., Mueller, S., Reese, D., Linder, R., Ahrens, S. & Frank Verheyen, F. (2013). How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus. The European Journal of Health Economics, 14(3), 551-568. https://doi:10.1007/s10198-012-0410-y google scholar

Atıflar

Biçimlendirilmiş bir atıfı kopyalayıp yapıştırın veya seçtiğiniz biçimde dışa aktarmak için seçeneklerden birini kullanın

DIŞA AKTAR

APA

Hussain, S.A., Al Tukmagi, H.F., Abdulrahman, Z.S., Sadeq, M.M., Hashim, D.N., Kadhim, R.S., Muayad Kubba, M.M., & Al Tukmagi, D.H. (2021). Evaluation of the adherence to antidiabetic medications among Iraqi patients with T2DM using the Iraqi antidiabetic medication adherence scale (IADMAS). İstanbul Journal of Pharmacy, 51(3), 307-312. https://doi.org/10.26650/IstanbulJPharm.2021.870571

AMA

Hussain S A, Al Tukmagi H F, Abdulrahman Z S, Sadeq M M, Hashim D N, Kadhim R S, Muayad Kubba M M, Al Tukmagi D H. Evaluation of the adherence to antidiabetic medications among Iraqi patients with T2DM using the Iraqi antidiabetic medication adherence scale (IADMAS). İstanbul Journal of Pharmacy. 2021;51(3):307-312. https://doi.org/10.26650/IstanbulJPharm.2021.870571

ABNT

Hussain, S.A.; Al Tukmagi, H.F.; Abdulrahman, Z.S.; Sadeq, M.M.; Hashim, D.N.; Kadhim, R.S.; Muayad Kubba, M.M.; Al Tukmagi, D.H. Evaluation of the adherence to antidiabetic medications among Iraqi patients with T2DM using the Iraqi antidiabetic medication adherence scale (IADMAS). İstanbul Journal of Pharmacy, [Publisher Location], v. 51, n. 3, p. 307-312, 2021.

Chicago: Author-Date Style

Hussain, Saad Abdulrahman, and Haydar Fakhri Al Tukmagi and Zainab Saad Abdulrahman and Maryem Maythem Sadeq and Dania Natheer Hashim and Rand Sabah Kadhim and Mohammed Mahdi Muayad Kubba and Dur Haydar Al Tukmagi. 2021. “Evaluation of the adherence to antidiabetic medications among Iraqi patients with T2DM using the Iraqi antidiabetic medication adherence scale (IADMAS).” İstanbul Journal of Pharmacy 51, no. 3: 307-312. https://doi.org/10.26650/IstanbulJPharm.2021.870571

Chicago: Humanities Style

Hussain, Saad Abdulrahman, and Haydar Fakhri Al Tukmagi and Zainab Saad Abdulrahman and Maryem Maythem Sadeq and Dania Natheer Hashim and Rand Sabah Kadhim and Mohammed Mahdi Muayad Kubba and Dur Haydar Al Tukmagi. “Evaluation of the adherence to antidiabetic medications among Iraqi patients with T2DM using the Iraqi antidiabetic medication adherence scale (IADMAS).” İstanbul Journal of Pharmacy 51, no. 3 (Jul. 2024): 307-312. https://doi.org/10.26650/IstanbulJPharm.2021.870571

Harvard: Australian Style

Hussain, SA & Al Tukmagi, HF & Abdulrahman, ZS & Sadeq, MM & Hashim, DN & Kadhim, RS & Muayad Kubba, MM & Al Tukmagi, DH 2021, 'Evaluation of the adherence to antidiabetic medications among Iraqi patients with T2DM using the Iraqi antidiabetic medication adherence scale (IADMAS)', İstanbul Journal of Pharmacy, vol. 51, no. 3, pp. 307-312, viewed 4 Jul. 2024, https://doi.org/10.26650/IstanbulJPharm.2021.870571

Harvard: Author-Date Style

Hussain, S.A. and Al Tukmagi, H.F. and Abdulrahman, Z.S. and Sadeq, M.M. and Hashim, D.N. and Kadhim, R.S. and Muayad Kubba, M.M. and Al Tukmagi, D.H. (2021) ‘Evaluation of the adherence to antidiabetic medications among Iraqi patients with T2DM using the Iraqi antidiabetic medication adherence scale (IADMAS)’, İstanbul Journal of Pharmacy, 51(3), pp. 307-312. https://doi.org/10.26650/IstanbulJPharm.2021.870571 (4 Jul. 2024).

MLA

Hussain, Saad Abdulrahman, and Haydar Fakhri Al Tukmagi and Zainab Saad Abdulrahman and Maryem Maythem Sadeq and Dania Natheer Hashim and Rand Sabah Kadhim and Mohammed Mahdi Muayad Kubba and Dur Haydar Al Tukmagi. “Evaluation of the adherence to antidiabetic medications among Iraqi patients with T2DM using the Iraqi antidiabetic medication adherence scale (IADMAS).” İstanbul Journal of Pharmacy, vol. 51, no. 3, 2021, pp. 307-312. [Database Container], https://doi.org/10.26650/IstanbulJPharm.2021.870571

Vancouver

Hussain SA, Al Tukmagi HF, Abdulrahman ZS, Sadeq MM, Hashim DN, Kadhim RS, Muayad Kubba MM, Al Tukmagi DH. Evaluation of the adherence to antidiabetic medications among Iraqi patients with T2DM using the Iraqi antidiabetic medication adherence scale (IADMAS). İstanbul Journal of Pharmacy [Internet]. 4 Jul. 2024 [cited 4 Jul. 2024];51(3):307-312. Available from: https://doi.org/10.26650/IstanbulJPharm.2021.870571 doi: 10.26650/IstanbulJPharm.2021.870571

ISNAD

Hussain, SaadAbdulrahman - Al Tukmagi, HaydarFakhri - Abdulrahman, ZainabSaad - Sadeq, MaryemMaythem - Hashim, DaniaNatheer - Kadhim, RandSabah - Muayad Kubba, MohammedMahdi - Al Tukmagi, DurHaydar. “Evaluation of the adherence to antidiabetic medications among Iraqi patients with T2DM using the Iraqi antidiabetic medication adherence scale (IADMAS)”. İstanbul Journal of Pharmacy 51/3 (Jul. 2024): 307-312. https://doi.org/10.26650/IstanbulJPharm.2021.870571

Cilt 51, Sayı 32021, S. 307-312

ZAMAN ÇİZELGESİ

Gönderim	31.01.2021
Kabul	30.09.2021
Çevrimiçi Yayınlanma	30.12.2021

LİSANS

Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.

İstanbul Journal of Pharmacy